Vivos Therapeutics, Inc. (VVOS): auditor change — Vivos Therapeutics cuts workforce 17%, accelerates cash flow positive target to Q1 2024

Vivos Therapeutics, Inc.

Reduced workforce by approximately 17% as part of operational efficiency initiatives.
Now expects to achieve positive cash flow by Q1 2024, a full quarter earlier than prior mid-2024 guidance.
Revenues expected to be relatively flat sequentially in H1 2023, with growth acceleration starting Q3 2023.
Dismissed Plante & Moran as auditor; engaged Moss Adams LLP effective May 3, 2023.

item 4.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Vivos Therapeutics, Inc. engaged Moss Adams LLP as its auditor.

Action: engagement
Auditor: Moss Adams LLP

Exact text from the filing

ay 3, 2023, the Committee approved the engagement of Moss Adams LLP (“ Moss Adams ”) as the Company’s new independent registered public accounting firm, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Vivos Therapeutics, Inc. dismissed Plante & Moran, PLLC as its auditor.

Action: dismissal
Auditor: Plante & Moran, PLLC
Successor: Moss Adams LLP

Exact text from the filing

(the “ Company ”) dismissed Plante & Moran, PLLC (“ P&M ”), the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

Browse all auditor changes →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-015936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.